November 24, 2025 — Leads & Copy — NeuroPace, Inc. has announced favorable Medicare reimbursement updates for its RNS® System under the CY 2026 OPPS and Medicare PFS final rules.
The Centers for Medicare & Medicaid Services (CMS) has significantly increased professional payments for neurosurgeons who implant and replace the RNS System, according to the CY 2026 Medicare PFS final rule. Payment rates for the initial implant procedure will increase by approximately 43% (+$530), while replacement procedure payments will increase by 45% (+$260).
NeuroPace Chief Executive Officer Joel Becker said the company is encouraged by CMS’ decision to meaningfully increase physician payment for RNS neurostimulator implant and replacement procedures. He added that the changes better reflect the physician resources used in treating patients with RNS therapy and should further support neurosurgeon adoption and procedure growth over time.
In the CY 2026 OPPS final rule, CMS has reassigned RNS System replacement procedures (CPT 61891) from APC 5464 (Level 4 Neurostimulator and Related Procedures) to APC 5465 (Level 5 Neurostimulator and Related Procedures). As a result, the average hospital Medicare reimbursement for RNS System replacements is set to increase by 47% (from $21,444 in CY 2025 to $31,526) starting January 1, 2026.
Becker stated that the company appreciates CMS’ decision to reassign RNS System replacement procedures to the highest-paying APC level for neurostimulators. He said this is a better reflection of the hospital resources required for these cases and should provide a helpful tailwind while supporting sustained access for Medicare beneficiaries treated in the outpatient setting, as replacement procedures become an increasingly meaningful contributor to the company’s business over time.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source.
This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
NeuroPace undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace’s views as of any date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of NeuroPace.
Joel Becker, Chief Executive Officer of NeuroPace
Source: NeuroPace, Inc.
